Replies to post #559426 on $Stock*Shop*Charts*News*Option$

[dDT]

Depomed beats by $0.14, beats on revenue

Depomed (NASDAQ:DEPO): Q4 EPS of $0.21 beats by $0.14.
Revenue (excl. non-cash royalty) of $47.65M (+111.8% Y/Y) beats by $2.99M.